GlassScriptPhysician profile
Wendy Ladawn Wilson
NPI 1386068690
$6,402.43
in general payments reported to CMS, 2019-2025
38 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,038 · 2022: $1,218 · 2023: $1,559 · 2024: $1,467 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,146.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.88 | 2021-2025 | |
| Novo Nordisk INC | $834.84 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $713.72 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $452.79 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $425.91 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $364.54 | 2021-2024 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.33 | 2021-2025 | Xifaxan, Trulance |
| Shield Therapeutics INC | $291.16 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.66 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $205.87 | 2021-2025 | Otezla, Repatha, Otezla |
| Esperion Therapeutics, INC. | $195.58 | 2021-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $142.94 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $128.68 | 2021-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $120.88 | 2022-2024 | |
| Glaxosmithkline, LLC. | $86.20 | 2023-2024 | Trelegy Ellipta |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.